eligibility_summary
Eligibility: R/R multiple myeloma with measurable disease, IMWG 2016 progression, ABBV-383 naive, ECOG <=2 (Arm C: <=1), Arm C must be suitable for outpatient dosing. Arm A: >=3 prior lines incl PI, IMiD, anti-CD38, no prior BCMA therapy. Arm B: >=2 lines incl PI, IMiD, anti-CD38 plus prior BCMA therapy (ADC or CAR-T). Arm C: >=2 lines incl PI, IMiD, anti-CD38. Exclusions: Arm A: prior BCMA therapy, Arm C: rapidly progressing disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05650632 tests ABBV-383, an investigational intravenous bispecific T‑cell–redirecting antibody (immunotherapy). Mechanism: ABBV-383 simultaneously binds BCMA (TNFRSF17) on malignant plasma cells and CD3 on T cells, forming an immune synapse that activates T cells to kill myeloma cells via perforin/granzyme release and cytokine signaling, aiming to minimize CRS via dose optimization (step-up and flat dosing). Targets: BCMA-expressing plasma cells in multiple myeloma, engages T-cell receptor/CD3 signaling to drive cytotoxicity, functionally impacts BCMA survival pathways (APRIL/BAFF). Cohorts include BCMA‑naïve and BCMA‑exposed patients.